Vaccines
RSSArticles
-
Can Maternal COVID-19 Vaccination Protect Newborns?
In this case control study, 537 case infants younger than 6 months of age who were admitted to the hospital with COVID-19 were compared to 512 control infants who were hospitalized for other reasons; 16% of the case infants and 29% of the control infants had been born to mothers who had been fully vaccinated against COVID-19 during the pregnancy. The effectiveness of maternal vaccination against infant hospitalization for COVID-19 was 52% overall, 80% during the Delta variant period, and 38% during the Omicron variant period. Effectiveness increased when the vaccine was received after 20 weeks of pregnancy.
-
Bivalent COVID-19 Vaccine (Booster Dose)
The FDA has amended the emergency use authorizations of two leading COVID-19 vaccines. Now, these new bivalent formulations can be used as a single booster dose (after primary or booster vaccination).
-
How Did Paralytic Polio Re-Emerge in the U.S.?
Most outbreaks globally are attributed to vaccine-derived polio, or type 2. Cases of the type 2 form of polio stem from the large-scale, global use of the oral polio vaccine, a solution that contains a live (but weakened) virus.
-
Kindergarten Vaccine Rates: Post-COVID
The COVID-19 pandemic caused disruption in healthcare delivery for everyone. Schools continue to struggle to meet the Healthy People 2030 Nationwide target of ≥ 95% coverage for measles, mumps, rubella (MMR) vaccination in kindergarteners, and COVID-19 did not help. Remarkably, the nationwide vaccine rate for children entering kindergarten in the 2020-2021 school year was decreased by only 1% for all vaccines compared with the previous year.
-
Safety of Infliximab After Live Vaccines
Despite concerns about the use of infliximab for children with Kawasaki disease shortly after administration of live vaccines, retrospective reviews do not show any vaccine-related infections following subsequent infliximab use.
-
Boosting with the New Bivalent COVID-19 Vaccines
The Centers for Disease Control and Prevention has made recommendations for the use of the newly approved bivalent COVID-19 booster vaccine.
-
Smallpox and Monkeypox Vaccine, Live, Non-Replicating (Jynneos)
Jynneos can be administered to prevent smallpox and monkeypox in adults age 18 years and older who are at high risk for contracting the infections.
-
FDA Authorizes Updated Boosters to Protect Against Omicron
Agency prepares for potential cold weather COVID-19 case spike with latest vaccine solution.
-
Is It Possible to Sway Hesitant Patients to Take the COVID-19 Vaccine?
A survey conducted in a small New York county reveals some challenges moving forward.
-
COVID-19 Infection More Likely to Inflame Heart Than Vaccine
Researchers noted patients were much more likely to be afflicted with myocarditis after a SARS-CoV-2 infection than after receiving a vaccine.